You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNicardipine
Accession NumberDB00622  (APRD00088)
TypeSmall Molecule
GroupsApproved
DescriptionA potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [PubChem]
Structure
Thumb
Synonyms
Cardene
Nicardipino
Nicardipinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cardene 20mg CapsulesCapsule20 mgOralHoffmann La Roche Limited1996-12-312001-07-19Canada
Cardene 30mg CapsulesCapsule30 mgOralHoffmann La Roche Limited1998-01-212001-07-19Canada
Cardene Cap 30mgCapsule30 mgOralSyntex Inc.1990-12-311998-09-03Canada
Cardene I.V.Injection2.5 mg/mLIntravenousEkr Therapeutics1992-01-30Not applicableUs
Cardene I.V.Injection, solution.2 mg/mLIntravenousEKR Therapeutics, Inc.1992-01-30Not applicableUs
Cardene I.V.Injection, solution.1 mg/mLIntravenousEKR Therapeutics, Inc.1992-01-30Not applicableUs
Cardene I.V.Injection, solution.1 mg/mLIntravenousEKR Therapeutics, Inc.1992-01-30Not applicableUs
Cardene I.V.Injection, solution.2 mg/mLIntravenousEKR Therapeutics, Inc.1992-01-30Not applicableUs
Cardene IVInjection, solution.1 mg/mLIntravenousChiesi USA, Inc.1992-01-30Not applicableUs
Cardene IVInjection, solution.2 mg/mLIntravenousChiesi USA, Inc.1992-01-30Not applicableUs
Cardene IVInjection, solution.2 mg/mLIntravenousChiesi USA, Inc.1992-01-30Not applicableUs
Cardene IVInjection, solution.1 mg/mLIntravenousChiesi USA, Inc.1992-01-30Not applicableUs
Cardene SRCapsule, extended release30 mg/1OralCarilion Materials Management1992-02-21Not applicableUs
Nicardipine HydrochlorideInjection2.5 mg/mLIntravenousWest Ward Pharmaceuticals Corp2012-03-02Not applicableUs
Nicardipine HydrochlorideInjection2.5 mg/mLIntravenousWest Ward Pharmaceuticals Corp2012-03-02Not applicableUs
Nicardipine HydrochlorideInjection2.5 mg/mLIntravenousSun Pharma Global Inc.2009-11-17Not applicableUs
Nicardipine HydrochlorideInjection25 mg/10mLIntravenousWest Ward Pharmaceuticals Corp2012-03-02Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nicardipine HydrochlorideCapsule20 mg/1OralEpic Pharma, LLC2010-05-05Not applicableUs
Nicardipine HydrochlorideInjection, solution2.5 mg/mLIntravenousAmerican Regent, Inc.2009-11-17Not applicableUs
Nicardipine HydrochlorideCapsule30 mg/1OralMylan Pharmaceuticals Inc.1996-07-19Not applicableUs
Nicardipine HydrochlorideInjection, solution2.5 mg/mLIntravenousMylan Institutional LLC2011-12-23Not applicableUs
Nicardipine HydrochlorideInjection, solution2.5 mg/mLIntravenousPharma Force, Inc.2009-11-17Not applicableUs
Nicardipine HydrochlorideCapsule30 mg/1OralEpic Pharma, LLC2010-05-05Not applicableUs
Nicardipine HydrochlorideInjection2.5 mg/mLIntravenousSandoz Inc.2009-11-17Not applicableUs
Nicardipine HydrochlorideCapsule20 mg/1OralCarilion Materials Management1996-07-19Not applicableUs
Nicardipine HydrochlorideCapsule30 mg/1OralCarilion Materials Management1996-07-19Not applicableUs
Nicardipine HydrochlorideCapsule20 mg/1OralAv Kare, Inc.2010-05-05Not applicableUs
Nicardipine HydrochlorideInjection2.5 mg/mLIntravenousWockhardt Limited2009-11-09Not applicableUs
Nicardipine HydrochlorideInjection2.5 mg/mLIntravenousSandoz Inc.2010-09-27Not applicableUs
Nicardipine HydrochlorideCapsule30 mg/1OralAvera Mc Kennan Hospital2015-07-16Not applicableUs
Nicardipine HydrochlorideCapsule30 mg/1OralAv Kare, Inc.2010-05-05Not applicableUs
Nicardipine HydrochlorideInjection2.5 mg/mLIntravenousWockhardt USA LLC.2009-11-09Not applicableUs
Nicardipine HydrochlorideInjection2.5 mg/mLIntravenousEmcure Pharmaceuticals Ltd.2009-11-17Not applicableUs
Nicardipine HydrochlorideCapsule20 mg/1OralMylan Pharmaceuticals Inc.1996-07-19Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CardeneRoche
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Nicardipine Hydrochloride
54527-84-3
Thumb
  • InChI Key: AIKVCUNQWYTVTO-UHFFFAOYNA-N
  • Monoisotopic Mass: 515.182313414
  • Average Mass: 515.986
DBSALT000499
Categories
UNIICZ5312222S
CAS number55985-32-5
WeightAverage: 479.525
Monoisotopic: 479.205635675
Chemical FormulaC26H29N3O6
InChI KeyZBBHBTPTTSWHBA-UHFFFAOYSA-N
InChI
InChI=1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3
IUPAC Name
3-{2-[benzyl(methyl)amino]ethyl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
Pharmacology
IndicationUsed for the management of patients with chronic stable angina and for the treatment of hypertension.
Structured Indications
PharmacodynamicsNicardipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nicardipine is similar to other peripheral vasodilators. Nicardipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Mechanism of actionBy deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, nicardipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
TargetKindPharmacological actionActionsOrganismUniProt ID
Voltage-dependent L-type calcium channel subunit alpha-1CProteinyes
inhibitor
HumanQ13936 details
Voltage-dependent L-type calcium channel subunit beta-2Proteinyes
inhibitor
HumanQ08289 details
Voltage-dependent L-type calcium channel subunit alpha-1DProteinyes
inhibitor
HumanQ01668 details
Voltage-dependent calcium channel subunit alpha-2/delta-1Proteinyes
inhibitor
HumanP54289 details
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AProteinunknown
inhibitor
HumanP54750 details
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BProteinunknown
inhibitor
HumanQ01064 details
Alpha-1A adrenergic receptorProteinunknown
antagonist
HumanP35348 details
Alpha-1B adrenergic receptorProteinunknown
antagonist
HumanP35368 details
Alpha-1D adrenergic receptorProteinunknown
antagonist
HumanP25100 details
Muscarinic acetylcholine receptor M1Proteinunknown
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinunknown
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinunknown
antagonist
HumanP20309 details
Muscarinic acetylcholine receptor M4Proteinunknown
antagonist
HumanP08173 details
Muscarinic acetylcholine receptor M5Proteinunknown
antagonist
HumanP08912 details
CalmodulinProteinunknown
other/unknown
HumanP62158 details
Related Articles
AbsorptionWhile nicardipine is completely absorbed, it is subject to saturable first pass metabolism and the systemic bioavailability is about 35% following a 30 mg oral dose at steady state.
Volume of distribution
  • 8.3 L/kg
Protein binding>95%
Metabolism

Nicardipine HCl is metabolized extensively by the liver.

Route of eliminationNicardipine has been shown to be rapidly and extensively metabolized by the liver.
Half life8.6 hours
Clearance
  • 0.4 L/hr∙kg [Following infusion]
ToxicityOral LD50 Rat = 184 mg/kg, Oral LD50 Mouse = 322 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Nicardipine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Nicardipine.Vet Approved
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Nicardipine.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Nicardipine.Experimental
AbirateroneThe serum concentration of Nicardipine can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Nicardipine is combined with Acebutolol.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Nicardipine.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Nicardipine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Nicardipine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Acetazolamide.Approved, Vet Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Nicardipine.Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Nicardipine.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Nicardipine.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Nicardipine.Approved
AjmalineThe metabolism of Ajmaline can be decreased when combined with Nicardipine.Approved
AlbendazoleThe serum concentration of Nicardipine can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nicardipine.Approved
AldosteroneThe serum concentration of Nicardipine can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Nicardipine can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Nicardipine can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Nicardipine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Nicardipine is combined with Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Nicardipine.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Nicardipine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Nicardipine.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Nicardipine.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Nicardipine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Nicardipine.Approved, Withdrawn
AmantadineThe serum concentration of Nicardipine can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Nicardipine.Approved, Investigational
AmifostineNicardipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Nicardipine.Approved
Aminohippuric acidThe serum concentration of Nicardipine can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Nicardipine.Approved, Withdrawn
AmiodaroneThe metabolism of Nicardipine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Nicardipine.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nicardipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Nicardipine.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Nicardipine.Approved
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Nicardipine.Approved
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Nicardipine.Approved
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Nicardipine.Approved, Vet Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Nicardipine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nicardipine.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Nicardipine.Approved
AmsacrineThe serum concentration of Nicardipine can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Nicardipine is combined with Amyl Nitrite.Approved
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Nicardipine.Investigational
AnagrelideNicardipine may increase the QTc-prolonging activities of Anagrelide.Approved
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Nicardipine.Approved, Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Nicardipine.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Nicardipine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Nicardipine can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Nicardipine.Approved
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Nicardipine.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Nicardipine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Nicardipine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Nicardipine is combined with Arotinolol.Approved
Arsenic trioxideNicardipine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherNicardipine may increase the QTc-prolonging activities of Artemether.Approved
AsenapineNicardipine may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe serum concentration of Nicardipine can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Nicardipine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Nicardipine.Approved
AtomoxetineThe metabolism of Nicardipine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Nicardipine can be increased when it is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Nicardipine is combined with Atosiban.Approved
Atracurium besylateNicardipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Nicardipine.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Nicardipine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nicardipine is combined with Azilsartan medoxomil.Approved
AzithromycinNicardipine may increase the QTc-prolonging activities of Azithromycin.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Nicardipine.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Nicardipine.Experimental
BarbitalBarbital may increase the hypotensive activities of Nicardipine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Barnidipine.Approved
BedaquilineNicardipine may increase the QTc-prolonging activities of Bedaquiline.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Nicardipine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nicardipine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Nicardipine.Withdrawn
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Nicardipine.Approved
BenzocaineThe serum concentration of Nicardipine can be increased when it is combined with Benzocaine.Approved
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Nicardipine.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Nicardipine.Approved
BepridilThe serum concentration of Nicardipine can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Nicardipine.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nicardipine.Approved
BethanidineBethanidine may increase the hypotensive activities of Nicardipine.Approved
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Nicardipine.Approved, Investigational
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Nicardipine.Approved
BimatoprostNicardipine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BiperidenThe serum concentration of Nicardipine can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nicardipine.Approved
BoceprevirThe metabolism of Nicardipine can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Bortezomib can be decreased when combined with Nicardipine.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Nicardipine.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nicardipine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nicardipine.Approved
BretyliumThe risk or severity of adverse effects can be increased when Nicardipine is combined with Bretylium.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Nicardipine.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Nicardipine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Nicardipine.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Nicardipine.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Nicardipine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Nicardipine.Approved
BucindololBucindolol may increase the hypotensive activities of Nicardipine.Investigational
BufuralolThe metabolism of Bufuralol can be decreased when combined with Nicardipine.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Bumetanide.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Nicardipine.Approved, Investigational
BupranololNicardipine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Nicardipine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Nicardipine can be decreased when combined with Bupropion.Approved
BuspironeThe serum concentration of Nicardipine can be increased when it is combined with Buspirone.Approved, Investigational
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Nicardipine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Nicardipine.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Nicardipine.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Nicardipine.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Nicardipine.Approved
CalciumThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium Acetate.Approved
Calcium carbonateThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium citrateThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium citrate.Approved
Calcium glubionateThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Nicardipine.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Nicardipine is combined with Canagliflozin.Approved
CandesartanThe metabolism of Candesartan can be decreased when combined with Nicardipine.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Nicardipine.Withdrawn
CandoxatrilCandoxatril may increase the hypotensive activities of Nicardipine.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Nicardipine is combined with Captopril.Approved
CarbamazepineThe metabolism of Nicardipine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Nicardipine is combined with Carbetocin.Approved
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Nicardipine.Approved
CarbomycinThe metabolism of Nicardipine can be decreased when combined with Carbomycin.Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Nicardipine.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Nicardipine.Approved
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Nicardipine.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Nicardipine.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Nicardipine.Approved
CarvedilolNicardipine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nicardipine.Approved
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Nicardipine.Approved, Investigational
CeliprololNicardipine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Nicardipine.Approved, Vet Approved
CeritinibThe serum concentration of Nicardipine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Nicardipine.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Nicardipine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Nicardipine.Approved
ChloramphenicolThe metabolism of Chloramphenicol can be decreased when combined with Nicardipine.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Nicardipine.Approved, Illicit
ChloroquineNicardipine may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Chlorothiazide.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Nicardipine.Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Nicardipine.Approved
ChlorpromazineNicardipine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Nicardipine.Approved
ChlorprothixeneThe serum concentration of Nicardipine can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nicardipine.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Nicardipine.Approved
CholecalciferolThe metabolism of Nicardipine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Nicardipine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Nicardipine can be decreased when it is combined with Cholic Acid.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Nicardipine.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Nicardipine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Cilnidipine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Nicardipine.Approved
CimetidineThe serum concentration of Nicardipine can be increased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Nicardipine can be decreased when combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Nicardipine.Approved
CiprofloxacinNicardipine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideNicardipine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Nicardipine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Nicardipine.Approved
ClarithromycinThe metabolism of Nicardipine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Nicardipine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Nicardipine.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Nicardipine can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Nicardipine.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Nicardipine.Approved, Investigational
ClomipramineThe serum concentration of Nicardipine can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Nicardipine.Approved
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Nicardipine resulting in a loss in efficacy.Approved, Nutraceutical
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Nicardipine.Approved, Illicit
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Nicardipine.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Nicardipine.Approved
CobicistatThe serum concentration of Nicardipine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Nicardipine.Approved
CocaineThe metabolism of Nicardipine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Nicardipine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Nicardipine.Approved
ColforsinThe serum concentration of Nicardipine can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Nicardipine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Nicardipine.Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nicardipine.Investigational
CrizotinibNicardipine may increase the QTc-prolonging activities of Crizotinib.Approved
CryptenamineNicardipine may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Nicardipine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Nicardipine.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Nicardipine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Nicardipine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Nicardipine.Approved
Cyproterone acetateThe serum concentration of Nicardipine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nicardipine.Approved
DabrafenibThe serum concentration of Nicardipine can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Nicardipine can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Nicardipine.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Nicardipine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Nicardipine.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Nicardipine.Approved, Investigational
DarifenacinThe metabolism of Nicardipine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Nicardipine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Nicardipine.Approved
DasatinibThe serum concentration of Nicardipine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Nicardipine can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Nicardipine.Approved
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Nicardipine.Experimental
DeferasiroxThe serum concentration of Nicardipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Nicardipine can be decreased when combined with Delavirdine.Approved
DeserpidineNicardipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Nicardipine is combined with Desflurane.Approved
DesipramineThe serum concentration of Nicardipine can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Nicardipine can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Nicardipine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Nicardipine.Approved, Illicit, Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Nicardipine.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Nicardipine.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Nicardipine.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Nicardipine.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Nicardipine.Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Nicardipine.Approved, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Nicardipine.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Diclofenamide.Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Nicardipine.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Nicardipine.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Nicardipine.Approved
DigoxinThe serum concentration of Nicardipine can be decreased when it is combined with Digoxin.Approved
DihydralazineNicardipine may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Nicardipine.Approved, Illicit
DihydroergotamineThe metabolism of Nicardipine can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Nicardipine.Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Nicardipine.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Nicardipine is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Nicardipine.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Nicardipine is combined with Dipyridamole.Approved
DisopyramideNicardipine may increase the QTc-prolonging activities of Disopyramide.Approved
DisulfiramThe metabolism of Nicardipine can be decreased when combined with Disulfiram.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Nicardipine.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Nicardipine.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Nicardipine.Approved
DomperidoneNicardipine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Nicardipine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Nicardipine.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Nicardipine.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Nicardipine.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Nicardipine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Nicardipine.Approved, Investigational
DoxorubicinThe serum concentration of Nicardipine can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Nicardipine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Nicardipine.Approved, Illicit
DronedaroneNicardipine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolNicardipine may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DuloxetineNicardipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Nicardipine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Nicardipine.Approved
EfavirenzThe serum concentration of Nicardipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Nicardipine.Approved
EfonidipineNicardipine may increase the hypotensive activities of Efonidipine.Approved
ElbasvirThe serum concentration of Nicardipine can be increased when it is combined with Elbasvir.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Nicardipine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Nicardipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Nicardipine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Nicardipine.Approved, Vet Approved
EnalaprilatNicardipine may increase the hypotensive activities of Enalaprilat.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Nicardipine.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Nicardipine.Investigational
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Nicardipine.Approved, Investigational
EnzalutamideThe serum concentration of Nicardipine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Nicardipine.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Nicardipine is combined with Eplerenone.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Nicardipine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Nicardipine is combined with Eprosartan.Approved
ErgonovineThe serum concentration of Nicardipine can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Nicardipine can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Nicardipine.Approved, Investigational
ErythromycinThe metabolism of Nicardipine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramNicardipine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Nicardipine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Nicardipine.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nicardipine.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Nicardipine.Approved, Investigational
EstradiolThe metabolism of Estradiol can be decreased when combined with Nicardipine.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Nicardipine can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Nicardipine can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Nicardipine.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Nicardipine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Nicardipine is combined with Etacrynic acid.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Nicardipine.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Nicardipine.Approved, Illicit
EtodolacThe metabolism of Etodolac can be decreased when combined with Nicardipine.Approved, Investigational, Vet Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Nicardipine.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Nicardipine.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Nicardipine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Nicardipine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Nicardipine.Approved
FamotidineThe metabolism of Famotidine can be decreased when combined with Nicardipine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Felodipine.Approved, Investigational
FenoldopamNicardipine may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe serum concentration of Nicardipine can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nicardipine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Nicardipine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Nicardipine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Nicardipine is combined with Fimasartan.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Nicardipine.Approved, Investigational
FlecainideNicardipine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Nicardipine.Approved
FluconazoleThe serum concentration of Nicardipine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Nicardipine.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Nicardipine.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Nicardipine.Approved, Illicit
FluoxetineNicardipine may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolNicardipine may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Nicardipine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Nicardipine can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Nicardipine.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Nicardipine.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Nicardipine.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Nicardipine.Approved
FluvoxamineThe metabolism of Nicardipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Nicardipine.Approved, Investigational
FosamprenavirThe metabolism of Nicardipine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Nicardipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nicardipine.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Nicardipine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Nicardipine.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Nicardipine can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidNicardipine may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Nicardipine.Approved
GavestinelThe metabolism of Gavestinel can be decreased when combined with Nicardipine.Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Nicardipine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Nicardipine.Approved
GemfibrozilThe metabolism of Nicardipine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinNicardipine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Nicardipine can be increased when it is combined with Genistein.Investigational
GliclazideThe metabolism of Gliclazide can be decreased when combined with Nicardipine.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Nicardipine.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Nicardipine.Approved
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Nicardipine.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Nicardipine.Approved
GlycerolThe serum concentration of Nicardipine can be increased when it is combined with Glycerol.Experimental
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Nicardipine.Experimental
GoserelinNicardipine may increase the QTc-prolonging activities of Goserelin.Approved
Gramicidin DThe serum concentration of Nicardipine can be increased when it is combined with Gramicidin D.Approved
GranisetronNicardipine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Nicardipine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Nicardipine.Withdrawn
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Nicardipine.Approved, Vet Approved
GuanabenzNicardipine may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Nicardipine.Approved
GuanethidineNicardipine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Nicardipine.Approved, Investigational
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Nicardipine.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Nicardipine.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nicardipine.Approved, Withdrawn
HalothaneThe metabolism of Halothane can be decreased when combined with Nicardipine.Approved, Vet Approved
HexamethoniumNicardipine may increase the hypotensive activities of Hexamethonium.Experimental
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Nicardipine.Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Nicardipine.Approved
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Nicardipine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Nicardipine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Nicardipine.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Nicardipine.Approved, Vet Approved
HydroflumethiazideNicardipine may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Nicardipine.Approved, Illicit
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Nicardipine.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Nicardipine.Approved
IbutilideNicardipine may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Nicardipine.Approved
IdelalisibThe serum concentration of Nicardipine can be increased when it is combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Nicardipine.Approved
IloperidoneNicardipine may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostIloprost may increase the hypotensive activities of Nicardipine.Approved, Investigational
ImatinibThe metabolism of Imatinib can be decreased when combined with Nicardipine.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Nicardipine is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Nicardipine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Nicardipine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Indapamide.Approved
IndenololNicardipine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Nicardipine can be decreased when combined with Indinavir.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Nicardipine.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Nicardipine.Approved, Investigational
IndoraminNicardipine may increase the hypotensive activities of Indoramin.Withdrawn
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Nicardipine.Approved
IproclozideIproclozide may increase the hypotensive activities of Nicardipine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Nicardipine.Withdrawn
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Nicardipine.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Nicardipine.Approved, Investigational
IsavuconazoniumThe metabolism of Nicardipine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nicardipine.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Nicardipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Nicardipine is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Nicardipine can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Nicardipine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Nicardipine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Nicardipine.Approved
ItraconazoleThe metabolism of Nicardipine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Nicardipine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Nicardipine.Approved, Vet Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Nicardipine.Approved
JosamycinThe metabolism of Nicardipine can be decreased when combined with Josamycin.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Nicardipine.Approved, Vet Approved
KetanserinNicardipine may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Nicardipine.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Nicardipine.Approved
KetoconazoleThe metabolism of Nicardipine can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Nicardipine.Approved, Vet Approved
KitasamycinThe metabolism of Nicardipine can be decreased when combined with Kitasamycin.Experimental
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Nicardipine.Approved
LacidipineNicardipine may increase the hypotensive activities of Lacidipine.Approved
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Nicardipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Nicardipine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Nicardipine.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Nicardipine.Approved, Investigational
LapatinibThe serum concentration of Nicardipine can be increased when it is combined with Lapatinib.Approved, Investigational
LatanoprostNicardipine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Nicardipine.Approved
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Nicardipine.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Nicardipine.Approved
LenvatinibNicardipine may increase the QTc-prolonging activities of Lenvatinib.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Nicardipine.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Nicardipine.Approved
LeuprolideNicardipine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Nicardipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Nicardipine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Levobupivacaine.Approved
LevodopaNicardipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinNicardipine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Nicardipine.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Nicardipine is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Nicardipine can be decreased when it is combined with Levothyroxine.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Nicardipine.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Nicardipine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Nicardipine.Approved
LiothyronineThe serum concentration of Nicardipine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Nicardipine can be decreased when it is combined with Liotrix.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Nicardipine is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Nicardipine.Approved
LofexidineNicardipine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Nicardipine.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Nicardipine.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Nicardipine.Approved
LopinavirThe metabolism of Nicardipine can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Nicardipine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Nicardipine.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Nicardipine.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Nicardipine.Approved
LovastatinThe metabolism of Nicardipine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Nicardipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Nicardipine can be increased when it is combined with Lumacaftor.Approved
LumefantrineNicardipine may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Nicardipine.Approved, Investigational
MacitentanThe metabolism of Macitentan can be decreased when combined with Nicardipine.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineNicardipine may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Nicardipine is combined with Mannitol.Approved, Investigational
MaprotilineThe serum concentration of Nicardipine can be increased when it is combined with Maprotiline.Approved
MebanazineMebanazine may increase the hypotensive activities of Nicardipine.Withdrawn
MebendazoleThe serum concentration of Nicardipine can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Mecamylamine.Approved
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Nicardipine.Approved
MefloquineThe serum concentration of Nicardipine can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Nicardipine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninMelatonin may decrease the antihypertensive activities of Nicardipine.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Nicardipine.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Nicardipine.Investigational, Withdrawn
MeprobamateThe serum concentration of Nicardipine can be increased when it is combined with Meprobamate.Approved, Illicit
MequitazineThe metabolism of Mequitazine can be decreased when combined with Nicardipine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Nicardipine.Approved
MestranolThe metabolism of Mestranol can be decreased when combined with Nicardipine.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Nicardipine.Approved
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Nicardipine.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Nicardipine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nicardipine.Approved
MethotrimeprazineThe metabolism of Nicardipine can be decreased when combined with Methotrimeprazine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Nicardipine.Approved, Vet Approved
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Nicardipine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nicardipine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Nicardipine is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Nicardipine.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nicardipine.Approved, Investigational
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Nicardipine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Nicardipine.Approved, Vet Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Nicardipine.Approved, Illicit, Withdrawn
MetipranololThe risk or severity of adverse effects can be increased when Nicardipine is combined with Metipranolol.Approved
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Nicardipine.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Nicardipine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Nicardipine.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Nicardipine.Approved
MetyrosineNicardipine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nicardipine.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Nicardipine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Nicardipine.Approved
MibefradilThe serum concentration of Nicardipine can be increased when it is combined with Mibefradil.Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Nicardipine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Nicardipine.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Nicardipine can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Nicardipine can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Nicardipine.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Nicardipine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nicardipine.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Nicardipine.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Nicardipine.Approved
MitomycinThe serum concentration of Nicardipine can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Nicardipine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Nicardipine can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MivacuriumNicardipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Nicardipine.Approved
ModafinilThe serum concentration of Nicardipine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Nicardipine is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Nicardipine.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Nicardipine.Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Nicardipine.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Nicardipine.Approved, Investigational
MoxifloxacinNicardipine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineNicardipine may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Nicardipine.Approved, Investigational
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Nicardipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nicardipine is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nicardipine is combined with Nadolol.Approved
NafcillinThe metabolism of Nicardipine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nicardipine.Approved
NaftopidilNicardipine may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Nicardipine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Nicardipine.Approved, Vet Approved
NaltrexoneThe serum concentration of Nicardipine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Nicardipine.Approved, Vet Approved
NaringeninThe serum concentration of Nicardipine can be increased when it is combined with Naringenin.Experimental
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Nicardipine.Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Nicardipine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Nicardipine.Approved, Investigational
NefazodoneThe metabolism of Nicardipine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Nicardipine can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Nicardipine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Nicardipine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Nicardipine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Nicardipine.Withdrawn
NicergolineThe metabolism of Nicergoline can be decreased when combined with Nicardipine.Approved
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Nicardipine.Approved, Vet Approved
NicorandilNicorandil may increase the hypotensive activities of Nicardipine.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Nicardipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Nifedipine.Approved
NiguldipineNicardipine may increase the hypotensive activities of Niguldipine.Experimental
NilotinibNicardipine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilutamideThe metabolism of Nilutamide can be decreased when combined with Nicardipine.Approved
NilvadipineNicardipine may increase the hypotensive activities of Nilvadipine.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Nicardipine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Nicardipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nicardipine.Approved
NitrazepamThe serum concentration of Nicardipine can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Nicardipine can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Nitric Oxide.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Nicardipine.Approved, Vet Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nicardipine is combined with Nitroglycerin.Approved, Investigational
NitroprussideNicardipine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Nicardipine.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Nicardipine.Approved
NorethisteroneThe serum concentration of Nicardipine can be decreased when it is combined with Norethisterone.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Nicardipine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Nicardipine.Approved, Vet Approved
ObinutuzumabNicardipine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Nicardipine.Withdrawn
OfloxacinNicardipine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Nicardipine.Approved, Investigational
OlaparibThe metabolism of Nicardipine can be decreased when combined with Olaparib.Approved
OleandomycinThe metabolism of Nicardipine can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nicardipine.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Nicardipine.Approved
OmapatrilatNicardipine may increase the hypotensive activities of Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Nicardipine.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Nicardipine.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Nicardipine.Approved
OsimertinibThe serum concentration of Nicardipine can be increased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Nicardipine.Approved
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Nicardipine.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nicardipine.Approved
OxprenololNicardipine may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Nicardipine.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Nicardipine.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Nicardipine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Nicardipine.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Nicardipine.Investigational
PalbociclibThe serum concentration of Nicardipine can be increased when it is combined with Palbociclib.Approved
PaliperidoneNicardipine may increase the QTc-prolonging activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Nicardipine can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Nicardipine.Approved, Investigational
PanobinostatThe serum concentration of Nicardipine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Nicardipine can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Papaverine.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Nicardipine.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Nicardipine.Approved
PargylinePargyline may increase the hypotensive activities of Nicardipine.Approved
ParoxetineThe metabolism of Nicardipine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Nicardipine.Approved
Peginterferon alfa-2bThe serum concentration of Nicardipine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Nicardipine is combined with Penbutolol.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nicardipine.Approved
PentobarbitalThe metabolism of Nicardipine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumNicardipine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nicardipine.Approved, Investigational
PerflutrenNicardipine may increase the QTc-prolonging activities of Perflutren.Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Nicardipine.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Nicardipine is combined with Perindopril.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Nicardipine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Nicardipine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Nicardipine.Withdrawn
PhenelzinePhenelzine may increase the hypotensive activities of Nicardipine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Nicardipine.Approved, Withdrawn
PheniprazinePheniprazine may increase the hypotensive activities of Nicardipine.Withdrawn
PhenobarbitalThe metabolism of Nicardipine can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineNicardipine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nicardipine.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Nicardipine.Approved
PhentolamineNicardipine may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Nicardipine.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Nicardipine.Approved, Vet Approved
PimozideThe serum concentration of Pimozide can be increased when it is combined with Nicardipine.Approved
PinacidilNicardipine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Nicardipine is combined with Pindolol.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Nicardipine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Nicardipine is combined with Pipamperone.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Nicardipine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Nicardipine.Approved
PirlindolePirlindole may increase the hypotensive activities of Nicardipine.Approved
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Nicardipine.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Nicardipine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Nicardipine.Withdrawn
Platelet Activating FactorThe serum concentration of Nicardipine can be decreased when it is combined with Platelet Activating Factor.Experimental
PodofiloxThe metabolism of Podofilox can be decreased when combined with Nicardipine.Approved
PolythiazideNicardipine may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Nicardipine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Nicardipine.Approved
PosaconazoleThe metabolism of Nicardipine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Nicardipine is combined with Pramipexole.Approved, Investigational
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Nicardipine.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Nicardipine.Approved
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Nicardipine.Approved, Vet Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Nicardipine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Nicardipine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Nicardipine.Approved, Vet Approved
PrimaquineNicardipine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Nicardipine can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Nicardipine can be increased when it is combined with Probenecid.Approved
ProcainamideNicardipine may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Nicardipine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Nicardipine.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Nicardipine.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Nicardipine.Approved, Vet Approved
PromethazineThe serum concentration of Nicardipine can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Nicardipine can be increased when it is combined with Propafenone.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Nicardipine.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Nicardipine.Approved, Investigational
ProtriptylineThe serum concentration of Nicardipine can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Nicardipine.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Nicardipine.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Nicardipine.Approved, Illicit
QuercetinThe serum concentration of Nicardipine can be increased when it is combined with Quercetin.Experimental
QuetiapineNicardipine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe serum concentration of Nicardipine can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Nicardipine is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Nicardipine.Approved
QuinineNicardipine may increase the QTc-prolonging activities of Quinine.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Nicardipine.Approved, Investigational
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Nicardipine.Experimental
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Nicardipine.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nicardipine.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Nicardipine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Nicardipine.Approved, Investigational
RapacuroniumNicardipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Nicardipine.Approved
ReboxetineThe serum concentration of Nicardipine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Nicardipine can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Nicardipine is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Nicardipine.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Nicardipine.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Nicardipine.Investigational
RescinnamineNicardipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nicardipine.Approved
RifabutinThe metabolism of Nicardipine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Nicardipine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Nicardipine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Nicardipine.Approved, Investigational
RilmenidineNicardipine may increase the hypotensive activities of Rilmenidine.Investigational
RilpivirineThe serum concentration of Nicardipine can be increased when it is combined with Rilpivirine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Nicardipine is combined with Riociguat.Approved
RisperidoneNicardipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Nicardipine can be decreased when combined with Ritonavir.Approved, Investigational
RituximabNicardipine may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Nicardipine.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Nicardipine.Investigational, Withdrawn
RolapitantThe serum concentration of Nicardipine can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Nicardipine.Approved, Investigational
RopiniroleThe metabolism of Nicardipine can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Nicardipine.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Nicardipine.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Nicardipine.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Nicardipine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Nicardipine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Nicardipine.Withdrawn
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Nicardipine.Experimental
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Nicardipine.Approved, Vet Approved
SaprisartanNicardipine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Nicardipine can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Nicardipine.Approved
ScopolamineThe serum concentration of Nicardipine can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Nicardipine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Nicardipine.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Nicardipine.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Nicardipine.Approved, Investigational
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Nicardipine.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Nicardipine.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Nicardipine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Nicardipine is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Nicardipine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Nicardipine.Approved
SiltuximabThe serum concentration of Nicardipine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Nicardipine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Nicardipine can be increased when it is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Nicardipine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Nicardipine.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Nicardipine.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Nicardipine.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Nicardipine is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Nicardipine.Approved
SolithromycinThe metabolism of Nicardipine can be decreased when combined with Solithromycin.Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Nicardipine.Approved, Investigational
SotalolNicardipine may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Nicardipine.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Nicardipine.Experimental
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Nicardipine.Experimental
SpiraprilNicardipine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Nicardipine.Approved
St. John's WortThe serum concentration of Nicardipine can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Nicardipine can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Nicardipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Nicardipine is combined with Streptokinase.Approved
StreptozocinThe serum concentration of Nicardipine can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Nicardipine is combined with Sufentanil.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Nicardipine.Approved
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Nicardipine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Nicardipine.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Nicardipine.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Nicardipine.Approved
SulfisoxazoleThe metabolism of Sulfisoxazole can be decreased when combined with Nicardipine.Approved, Vet Approved
SumatriptanThe serum concentration of Nicardipine can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Nicardipine can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenThe metabolism of Suprofen can be decreased when combined with Nicardipine.Approved, Withdrawn
TacrineThe serum concentration of Nicardipine can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Nicardipine can be decreased when it is combined with Tacrolimus.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Nicardipine.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Nicardipine.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Nicardipine resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Nicardipine.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Nicardipine.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Nicardipine.Experimental
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Nicardipine.Approved
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Nicardipine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Nicardipine.Investigational, Withdrawn
TelaprevirThe metabolism of Nicardipine can be decreased when combined with Telaprevir.Approved
TelavancinNicardipine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Nicardipine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Nicardipine is combined with Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Nicardipine.Approved
TemocaprilNicardipine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Nicardipine.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Nicardipine.Approved
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Nicardipine.Approved
TerazosinThe risk or severity of adverse effects can be increased when Nicardipine is combined with Terazosin.Approved
TerbinafineThe metabolism of Nicardipine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Nicardipine.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Nicardipine.Withdrawn
TeriflunomideThe metabolism of Nicardipine can be decreased when combined with Teriflunomide.Approved
TerlipressinNicardipine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneThe serum concentration of Nicardipine can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Nicardipine.Approved, Investigational
TetrabenazineNicardipine may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Nicardipine.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Nicardipine.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Nicardipine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Nicardipine.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Nicardipine.Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Nicardipine.Approved
TiboloneNicardipine may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Nicardipine.Approved
TiclopidineThe metabolism of Nicardipine can be decreased when combined with Ticlopidine.Approved
TicrynafenNicardipine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Nicardipine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Nicardipine.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Nicardipine.Approved
TipranavirThe metabolism of Nicardipine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Nicardipine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Nicardipine.Approved, Investigational
TolazolineNicardipine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Nicardipine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Nicardipine is combined with Tolcapone.Approved, Withdrawn
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Nicardipine.Approved, Vet Approved
ToloxatoneToloxatone may increase the hypotensive activities of Nicardipine.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Nicardipine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Nicardipine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Nicardipine.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Nicardipine.Approved
ToremifeneNicardipine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Nicardipine.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Nicardipine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nicardipine.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nicardipine.Experimental
TranylcypromineThe metabolism of Nicardipine can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Nicardipine.Approved
TravoprostTravoprost may increase the hypotensive activities of Nicardipine.Approved
TrazodoneThe serum concentration of Nicardipine can be decreased when it is combined with Trazodone.Approved, Investigational
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Nicardipine.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Nicardipine.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nicardipine.Approved
TrichlormethiazideNicardipine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Nicardipine can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Nicardipine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimazosinNicardipine may increase the hypotensive activities of Trimazosin.Experimental
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Nicardipine.Approved
TrimethaphanNicardipine may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Nicardipine.Approved, Vet Approved
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nicardipine.Approved, Investigational
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Nicardipine.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Nicardipine.Withdrawn
TroleandomycinThe metabolism of Nicardipine can be decreased when combined with Troleandomycin.Approved
TylosinThe metabolism of Nicardipine can be decreased when combined with Tylosin.Vet Approved
UdenafilUdenafil may increase the antihypertensive activities of Nicardipine.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Nicardipine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Nicardipine.Approved
UnoprostoneNicardipine may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Nicardipine.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Nicardipine.Approved, Investigational
ValsartanThe metabolism of Valsartan can be decreased when combined with Nicardipine.Approved, Investigational
VandetanibNicardipine may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the antihypertensive activities of Nicardipine.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Nicardipine.Approved
VemurafenibNicardipine may increase the QTc-prolonging activities of Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Nicardipine.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Nicardipine.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Nicardipine.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Nicardipine.Investigational
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Nicardipine.Approved
VinblastineThe serum concentration of Nicardipine can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Nicardipine.Approved, Investigational
VincristineThe serum concentration of Nicardipine can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Nicardipine can be increased when it is combined with Vinorelbine.Approved, Investigational
VinpocetineNicardipine may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Nicardipine.Approved
VoriconazoleThe metabolism of Nicardipine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Nicardipine.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Nicardipine.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Nicardipine.Approved, Investigational, Withdrawn
XylometazolineNicardipine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Nicardipine.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Nicardipine.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Nicardipine.Approved
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Nicardipine.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Nicardipine.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Nicardipine.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Nicardipine can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneNicardipine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Nicardipine.Approved
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Nicardipine.Approved
ZuclopenthixolNicardipine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Grapefruit and grapefruit juice should be avoided throughout treatment. Grapefruit can increase serum levels of this product.
  • Take without regard to meals.
References
Synthesis Reference

Takashi Sonobe, Hiroitsu Kawata, Masayoshi Aruga, Tadayoshi Ohmura, Satoru Yoneya, Chiharu Yamada, Yukio Kubota, “Composition for long acting nicardipine preparation and process of producing the composition.” U.S. Patent US4758437, issued March, 1979.

US4758437
General ReferencesNot Available
External Links
ATC CodesC08CA04
AHFS Codes
  • 24:28.08
PDB EntriesNot Available
FDA labelDownload (1.26 MB)
MSDSDownload (106 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.932
Blood Brain Barrier-0.9549
Caco-2 permeable-0.83
P-glycoprotein substrateSubstrate0.8581
P-glycoprotein inhibitor IInhibitor0.9036
P-glycoprotein inhibitor IIInhibitor0.8253
Renal organic cation transporterNon-inhibitor0.7502
CYP450 2C9 substrateNon-substrate0.8296
CYP450 2D6 substrateNon-substrate0.5554
CYP450 3A4 substrateSubstrate0.7228
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8558
Ames testNon AMES toxic0.562
CarcinogenicityNon-carcinogens0.7262
BiodegradationNot ready biodegradable0.9604
Rat acute toxicity2.9030 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.7332
hERG inhibition (predictor II)Non-inhibitor0.7316
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ekr therapeutics inc
  • Amneal pharmaceutical
  • Barr laboratories inc
  • Mylan pharmaceuticals inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Bedford laboratories div ben venue laboratories inc
  • Bioniche pharma usa llc
  • Exela pharma sciences
  • Navinta llc
  • Pharmaforce inc
  • Sun pharma global inc
  • Wockhardt ltd
Packagers
Dosage forms
FormRouteStrength
CapsuleOral20 mg
CapsuleOral30 mg
Injection, solutionIntravenous.1 mg/mL
Injection, solutionIntravenous.2 mg/mL
Capsule, extended releaseOral30 mg/1
CapsuleOral20 mg/1
CapsuleOral30 mg/1
InjectionIntravenous2.5 mg/mL
InjectionIntravenous25 mg/10mL
Injection, solutionIntravenous2.5 mg/mL
Prices
Unit descriptionCostUnit
Cardene SR 60 60 mg 12 Hour Capsule Bottle142.91USD bottle
Nicardipine 25 mg/10 ml ampule25.01USD ml
Nicardipine 25 mg/10 ml vial10.42USD ml
Cardene SR 45 mg 12 Hour Capsule3.22USD capsule
Cardene sr 45 mg capsule2.9USD capsule
Cardene sr 60 mg capsule sa2.29USD capsule
Cardene SR 30 mg 12 Hour Capsule2.02USD capsule
Cardene sr 45 mg capsule sa1.91USD capsule
Cardene-dex 40 mg/200 ml iv1.35USD ml
Cardene-nacl 40 mg/200 ml iv1.35USD ml
Cardene 30 mg capsule1.28USD capsule
Cardene sr 30 mg capsule sa1.21USD capsule
Cardene sr 30 mg capsule0.87USD capsule
Cardene 20 mg capsule0.8USD capsule
NiCARdipine HCl 30 mg capsule0.68USD capsule
Cardene-dex 20 mg/200 ml soln0.67USD ml
Cardene-nacl 20 mg/200 ml soln0.67USD ml
Nicardipine 30 mg capsule0.66USD capsule
NiCARdipine HCl 20 mg capsule0.48USD capsule
Nicardipine 20 mg capsule0.46USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5164405 No1992-11-172009-11-17Us
US7612102 No2007-12-262027-12-26Us
US7659291 No2007-04-182027-04-18Us
US8455524 No2007-04-182027-04-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point136-138 °CPhysProp
water solubility2.2 mg/LNot Available
logP3.82SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.00247 mg/mLALOGPS
logP4.34ALOGPS
logP3.56ChemAxon
logS-5.3ALOGPS
pKa (Strongest Basic)8.18ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area113.69 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity134.8 m3·mol-1ChemAxon
Polarizability49.95 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassHydropyridines
Direct ParentDihydropyridinecarboxylic acids and derivatives
Alternative Parents
Substituents
  • Nitrobenzene
  • Dihydropyridinecarboxylic acid derivative
  • Phenylmethylamine
  • Benzylamine
  • Aralkylamine
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Vinylogous amide
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Methyl ester
  • Organic nitro compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Organic nitrite
  • C-nitro compound
  • Carboxylic acid ester
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Enamine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic zwitterion
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB2
Uniprot ID:
Q08289
Molecular Weight:
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1D
Uniprot ID:
Q01668
Molecular Weight:
245138.75 Da
References
  1. Bell DC, Butcher AJ, Berrow NS, Page KM, Brust PF, Nesterova A, Stauderman KA, Seabrook GR, Nurnberg B, Dolphin AC: Biophysical properties, pharmacology, and modulation of human, neuronal L-type (alpha(1D), Ca(V)1.3) voltage-dependent calcium currents. J Neurophysiol. 2001 Feb;85(2):816-27. [PubMed:11160515 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-contraction coupling (By similarity).
Gene Name:
CACNA2D1
Uniprot ID:
P54289
Molecular Weight:
124566.93 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a higher affinity for cGMP than for cAMP.
Gene Name:
PDE1A
Uniprot ID:
P54750
Molecular Weight:
61251.38 Da
References
  1. Sharma RK, Wang JH, Wu Z: Mechanisms of inhibition of calmodulin-stimulated cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists. J Neurochem. 1997 Aug;69(2):845-50. [PubMed:9231746 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a preference for cGMP as a substrate.
Gene Name:
PDE1B
Uniprot ID:
Q01064
Molecular Weight:
61379.235 Da
References
  1. Sharma RK, Wang JH, Wu Z: Mechanisms of inhibition of calmodulin-stimulated cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists. J Neurochem. 1997 Aug;69(2):845-50. [PubMed:9231746 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Titin binding
Specific Function:
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Gene Name:
CALM1
Uniprot ID:
P62158
Molecular Weight:
16837.47 Da
References
  1. Thayer SA, Fairhurst AS: The interaction of dihydropyridine calcium channel blockers with calmodulin and calmodulin inhibitors. Mol Pharmacol. 1983 Jul;24(1):6-9. [PubMed:6865927 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm Res. 2000 Oct;17(10):1189-97. [PubMed:11145223 ]
  2. Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE: Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm Res. 2000 Dec;17(12):1456-60. [PubMed:11303953 ]
  3. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
  4. Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65. [PubMed:12128170 ]
  5. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  6. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465 ]
  7. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 11, 2016 02:40